News – Page 907 – Endpoints News

Pelosi drug pricing bill promises savings, but could gag R&D — CBO analysis

6 years ago

Pfizer takes aim at a flagship franchise at Sanofi and Regeneron — and scores a few direct hits

6 years ago

First place finish: Eli Lilly just moved to franchise leader with their second migraine drug OK in 1 year

6 years ago

ARCH, SoftBank-backed Vir Biotechnology underwhelms with $143 million IPO

6 years ago

Court green-lights Clovis case after detailing evidence the board ‘ignored red flags’ on false safety and ...

6 years ago

Northwest Bio still hanging on; Five Prime's latest round of layoffs claims 70

6 years ago

Zosano Pharma CEO passes baton down to successor; James Sapirstein takes the helm at AzurRx

6 years ago

Microcap Aridis recruits Takeda vet Paul Mendelman to steer late-stage antibody programs in infectious diseases

6 years ago

Long term data echo safety profile of Gilead, Galapagos' potential blockbuster JAK inhibitor

6 years ago

Researchers find 15% of trials could be replicated using real world data

6 years ago

Ex-AbbVie partner Principia posts encouraging PhII results for its BTK-inhibitor

6 years ago

Roche vice-chair: Let's repair the damage that short-term profit drive has done to the planet

6 years ago

In reversal, NICE backs Rubraca after Clovis agrees to a price cut

6 years ago

J&J hands off non-opioid painkiller to an upstart in the race for next-gen analgesics

6 years ago

Zantac pulled off shelves due to cancer scare; The end of the road for Motif Bio

6 years ago

Flow of US biotech VC dollars on track to match record 2018 levels — China? Not so much

6 years ago

AbbVie uncoupling costs Reata $330M in cold, hard cash

6 years ago

Bill Gates backs Ginkgo Bioworks' $350M raise to fuel the buzzy synthetic biology 'revolution'

6 years ago

Neglected on Wall Street, little Stealth Bio finds an affluent chum with $30M in cash and high hopes for their PhIII ...

6 years ago

Parexel embraces real world evidence, enlisting Datavant to drill it into CRO workflow

6 years ago

Wall Street trims cancer drug developer BioNTech's unicorn valuation

6 years ago

Flemming Ørnskov takes on a new challenge, driving a $10B dermatology spinout with some big plans for growth

6 years ago

UCB bags a rival to Soliris in $2.1B buyout deal — but will an increasingly vigilant FTC sign off?

6 years ago

Shionogi celebrates antibiotic win in pneumonia just ahead of its date with FDA regulators

6 years ago

First page Previous page 904 905 906907908 909 910 Next page Last page